Karine Gauthier, University of Ottawa

Research

Antimicrobial Resistance Biomarker C.Difficile Infection Chimeric Antigen Receptor T-Cell Therapy Feasibility Hematopoietic Stem Cell Transplantation Microbiome Pilot

Latest papers

Inter-observer reliability of the HERDOO2 clinical decision rule.
Thrombosis research · 2016 · first author

All 1 publications

Latest funding

Oral Vancomycin for the Prevention of C. difficile Infection in High-Risk HCT and CAR-T Patients (VAPOR-HCT): A Pilot Randomized Placebo-Controlled Trial
CIHR · 2025 · Principal investigator
$100,000
Low-dose direct oral anticoagulant compared to aspirin for the thromboprophylaxis of patients with JAK2-positive myeloproliferative neoplasms
CIHR · 2024 · Co-investigator
$1,350,226

All 2 grants and awards

1 publications.

01

Inter-observer reliability of the HERDOO2 clinical decision rule.

Gauthier K, Le Gal G, Shivakumar S, Anderson D, Chagnon I, Solymoss S, Ortel T, Yeo E, Kearon C, Rodger M

Thrombosis research2016First author

DOI: 10.1016/j.thromres.2016.03.015 PMID: 27031923

Oral Vancomycin for the Prevention of C. difficile Infection in High-Risk HCT and CAR-T Patients (VAPOR-HCT): A Pilot Randomized Placebo-Controlled Trial

Principal investigatorCIHR2025Project Grant - Priority Announcement - Cancer Survivorship

Principal investigators: MacFadden, Derek R; Atkins, Harold L; Buchan, Catharine A; Cheng, Matthew P; Climans, Troy; Coburn, Bryan A; Daneman, Nick; Gauthier, Karine; Hay, Annette; Kabbani, Dima; Kekre, Natasha; Kennah, Michael; McIntyre, Lauralyn A; Mertz, Dominik; Monteith, Bethany E; Mortimer, Leanne M; Purssell, Andrew; Taljaard, Monica; Tsang, Corey

Keywords: Antimicrobial Resistance; Biomarker; C.Difficile Infection; Chimeric Antigen Receptor T-Cell Therapy; Feasibility; Hematopoietic Stem Cell Transplantation; Microbiome; Pilot; Prophylaxis; Randomized Trial

$100,000

Low-dose direct oral anticoagulant compared to aspirin for the thromboprophylaxis of patients with JAK2-positive myeloproliferative neoplasms

Co-investigatorCIHR2024Project Grant

Principal investigators: Kimpton, Miriam; Delluc, Aurelien

Keywords: Cancer; Cardiovascular Outcomes; Randomized Controlled Trial; Thrombosis

$1,350,226

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Medicine
Department of Medicine
Other

Co-authors at University of Ottawa, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.

David Anderson

Medicine

1 shared papers, latest 2016

Marc Rodger

Department of Medicine

1 shared papers, latest 2016

Sudeep Shivakumar

Medicine

1 shared papers, latest 2016

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Mention their CIHR grant from 2025

Subject: Prospective PhD student: Antimicrobial Resistance Dear Professor Gauthier, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Inter-observer reliability of the HERDOO2 clinical decision rule." (2016), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Oral Vancomycin for the Prevention of C. difficile Infection in High-Risk HCT and CAR-T Patients (VAPOR-HCT): A Pilot Randomized Placebo-Controlled Trial" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]